Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + prednisone + procarbazine + vincristine
- Development stage
- Unknown
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This drug is a combination chemotherapy regimen known as COPP, consisting of four agents: - Cyclophosphamide: an alkylating agent that interferes with DNA replication and RNA transcription by cross-linking DNA strands. - Prednisone: a corticosteroid that induces apoptosis in certain cancer cells and has anti-inflammatory effects. - Procarbazine: an alkylating agent that causes DNA damage leading to cell death. - Vincristine (vincristine sulfate): a vinca alkaloid that inhibits microtubule formation in mitotic spindle, arresting cell division. The combination works synergistically to kill cancer cells through different mechanisms. It is primarily used for the treatment of Hodgkin's disease (Hodgkin lymphoma) and has also been used in non-Hodgkin lymphoma. The regimen was developed as part of multi-agent chemotherapy protocols for advanced lymphomas. Each component drug is FDA-approved individually for cancer treatment.
- Other names
- COPP
02
Targets
GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on cyclophosphamide + prednisone + procarbazine + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + prednisone + procarbazine + vincristine.